<?xml version="1.0" encoding="UTF-8"?>
<p id="par0180">
 <italic>In vivo</italic> studies showed that several circulating chemokines (CXCL8, CCL2 and CXCL10) and inflammatory cytokines (IL-1, IL-6 and IL-12) were elevated in patients with SARS-CoV [
 <xref rid="bib0340" ref-type="bibr">68</xref>,
 <xref rid="bib0345" ref-type="bibr">69</xref>]. CXCL10 was also considered an excellent prognostic marker for SARS disease progression [
 <xref rid="bib0350" ref-type="bibr">70</xref>,
 <xref rid="bib0355" ref-type="bibr">71</xref>]. In particular, Jiang et al. showed that CXCL 10 serum levels were significantly increased during the early stage of SARS, and remained elevated until resolution. Moreover, persistently elevated CXCL10 serum levels during follow-up were predictive of a worse outcome of the infection [
 <xref rid="bib0355" ref-type="bibr">71</xref>]
</p>
